Marcelo Bigal, Ventus Therapeutics CEO
September 29, 2022 07:08 AM EDT
Deals

No­vo Nordisk joins No­var­tis, Roche in NL­RP3 are­na, bet­ting $70M cash on NASH, car­diometa­bol­ic us­es

Amber Tong

As a drug tar­get, the NL­RP3 in­flam­ma­some has drawn se­ri­ous in­ter­est from Big Phar­ma, in­spir­ing a se­ries of M&A deals from No­var­tis and Roche on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ma­jor FDA staff cuts would slow drug re­views, ex­perts say

Up­dat­ed: Bay Area biotech VC to shut down 15 months af­ter launch, sources say, af­ter key in­vestor pulls out

Bain buys Mit­subishi Tan­abe Phar­ma in $3.3B bet on Japan

Sen­a­tors ask FDA to dig in­to 'mis­lead­ing' Su­per Bowl ad from Hims

Roche heads to FDA with Gazy­va re­sults in a form of lu­pus

Bel­gian reg­u­la­tor rec­om­mends block­ing In­di­an drug­mak­er's API pro­duc­tion

A service from the Financial Times